Roche: positive phase III results in influenza

(CercleFinance.com) - Roche reports positive top-line results from the Phase III CENTERSTONE study of the antiviral Xofluza, which met its primary endpoint by demonstrating a reduction in the transmission of influenza viruses.


A single oral dose of Xofluza taken by influenza-infected individuals significantly reduced the likelihood of other members of their household contracting the virus. The product was well tolerated and no new safety signals were identified.

The Swiss healthcare group says that this is the first time that an antiviral used in the treatment of a respiratory viral disease has demonstrated a transmission reduction benefit in a global Phase III study.


Copyright (c) 2024 CercleFinance.com. All rights reserved.